MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Edesa Biotech, Inc. (EDSA)

Edesa Biotech, Inc. (EDSA)

|||

Cash Flow Overview

Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Accounts payable and accrued lia...
    • Share-based compensation
    • Depreciation and amortization
Negative Cash Flow Breakdown
    • Net loss
    • Payments for issuance costs of c...
    • Effect of exchange rate changes ...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents at beginning of period
-
-
10,792,172
1,037,320
Net loss
-5,407,611
-4,218,332
-2,247,669
-2,228,358
Depreciation and amortization
25,644
25,872
25,460
25,868
Share-based compensation
547,463
484,853
399,862
404,425
Gain on loan forgiveness
-
-
-
0
Accounts and other receivable
16,140
-211,345
-217,387
359,828
Prepaid expenses and other current assets
25,313
-36,124
155,922
-34,477
Accounts payable and accrued liabilities
1,793,284
1,443,516
-326,452
402,422
Net cash used in operating activities
-3,082,673
-2,016,622
-2,087,334
-1,720,994
Proceeds from issuance of common shares
3,499,991
0
3,497,825
220,501
Proceeds from issuance of series a-1 preferred shares and warrants
0
0
0
0
Proceeds from issuance of series b-1 preferred shares-Series B1Preferred Stock
0
0
-
0
Payments for issuance costs of common shares-Common Stock And Warrants
53,054
8,980
142,406
34,018
Payments for issuance costs of common shares-Preferred Stock
0
0
-
0
Payment for issuance costs of warrants
0
0
-
0
Repayment of debt
-
-
-
0
Net cash provided by financing activities
3,446,937
-8,980
3,355,419
186,483
Effect of exchange rate changes on cash and cash equivalents
-35,427
-22,463
-8,509
-35,007
Net change in cash and cash equivalents
328,837
-2,048,065
1,259,576
-1,569,518
Cash and cash equivalents, beginning of the period
10,003,683
10,792,172
-
-
Cash and cash equivalents at end of period
-
-
12,051,748
10,792,172
Cash and cash equivalents, end of the period
10,332,520
10,003,683
-
-
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon shares$3,499,991 (-53.32%↓ Y/Y)Net cash provided byfinancing activities$3,446,937 (-79.54%↓ Y/Y)Canceled cashflow$53,054 Net change in cashand cash...$328,837 (-97.10%↓ Y/Y)Canceled cashflow$3,118,100 Payments for issuancecosts of common...$53,054 (-82.01%↓ Y/Y)Accounts payable andaccrued liabilities$1,793,284 (260.41%↑ Y/Y)Share-based compensation$547,463 (68.34%↑ Y/Y)Depreciation andamortization$25,644 (-72.55%↓ Y/Y)Net cash used inoperating activities-$3,082,673 (44.96%↑ Y/Y)Effect of exchange ratechanges on cash and cash...-$35,427 (-143.62%↓ Y/Y)Canceled cashflow$2,366,391 Net loss-$5,407,611 (-9.09%↓ Y/Y)Prepaid expenses andother current assets$25,313 (134.51%↑ Y/Y)Accounts and otherreceivable$16,140 (-11.12%↓ Y/Y)